Her 2-Neu / Ki67 Immunohistochemistry at Chughtai Lab

Her 2-Neu / Ki67 (Staining) at Chughtai Lab

The Her 2-Neu / Ki67 (Staining) at Chughtai Lab is a highly specialized immunohistochemistry (IHC) diagnostic panel that plays a pivotal role in the modern management of breast cancer and other malignancies. This advanced laboratory test is performed on tissue samples obtained via biopsy or surgical resection. It evaluates two critical biomarkers: Human Epidermal Growth Factor Receptor 2 (HER2/neu) and the Ki-67 proliferation antigen. Together, these markers provide essential prognostic and predictive information, allowing oncologists to understand the biological behavior of the tumor, estimate the patient’s prognosis, and design highly personalized, targeted treatment strategies.

HER2/neu is a proto-oncogene located on chromosome 17 that encodes a 185 kDa transmembrane glycoprotein receptor with intrinsic tyrosine kinase activity. This receptor belongs to the epidermal growth factor receptor (EGFR) family and is involved in cell growth, survival, and differentiation pathways. In approximately 15% to 20% of breast cancers, the HER2 gene is amplified, leading to an overexpression of the HER2 protein on the cell membrane. This overexpression drives aggressive tumor growth, increases the risk of recurrence, and historically correlated with a poor prognosis. However, the identification of HER2 overexpression is of immense therapeutic value because it makes the tumor highly susceptible to HER2-targeted therapies, such as the monoclonal antibody trastuzumab (Herceptin), pertuzumab, and antibody-drug conjugates like trastuzumab emtansine (T-DM1).

Ki-67 is a cellular marker for proliferation. It is a non-histone nuclear protein that is expressed during all active phases of the cell cycle—specifically G1, S, G2, and mitosis—but is strictly absent in resting cells (G0 phase). Because of this cell-cycle-specific expression, the Ki-67 proliferation index (the percentage of tumor cells showing nuclear positivity for Ki-67) serves as an exceptionally reliable measure of the tumor’s growth fraction. A high Ki-67 index indicates a rapidly growing, highly proliferative tumor, which is often associated with higher histological grades, a greater likelihood of lymph node metastasis, and a higher risk of early recurrence. Conversely, a low Ki-67 index indicates a slow-growing, indolent tumor.

At Chughtai Lab, this staining panel is performed using state-of-the-art automated immunohistochemistry platforms. These systems ensure precise reagent dispensing, optimal incubation times, and standardized antigen retrieval, minimizing inter-run variability and ensuring the highest level of diagnostic accuracy. The resulting slides are interpreted by experienced Consultant Pathologists who adhere strictly to the latest American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) guidelines.

Clinical Procedure: What to Expect

Patient Preparation

Because the Her 2-Neu / Ki67 staining is an immunohistochemical analysis performed on tissue specimens that have already been surgically removed or biopsied, patients do not need to undergo any direct physical preparation for the staining process itself. There is no requirement for fasting, dietary restrictions, or medication adjustments specifically for this laboratory test. However, to ensure a seamless and accurate testing process at Chughtai Lab, patients and healthcare providers must follow these essential preparation guidelines:

• Submit High-Quality Tissue Blocks: The patient must provide the formalin-fixed, paraffin-embedded (FFPE) tissue block, commonly referred to as the “paraffin block” or “tumor block,” along with the corresponding stained glass slides from the original histopathology examination.
• Provide Clinical Documentation: It is mandatory to submit the original histopathology report and a detailed clinical history. This should include the patient’s age, anatomical site of the biopsy, previous cancer treatments, and the specific clinical questions the oncologist wishes to address.
• Ensure Proper Tissue Fixation: The accuracy of immunohistochemistry depends heavily on pre-analytical factors. The tissue must be fixed in 10% neutral buffered formalin within one hour of surgical removal (cold ischemia time) and fixed for a minimum of 6 hours and a maximum of 72 hours. Improper fixation can lead to false-negative or false-positive results.
• Pathology Referral Form: A completed referral form signed by the treating oncologist or surgeon must accompany the specimen, clearly indicating the request for HER2/neu and Ki-67 immunohistochemical staining.
• Handling of Slides: If paraffin blocks cannot be provided, patients may submit unstained, positively charged slides cut at 3-4 microns. These slides must be processed and stained promptly to prevent antigen degradation, which can occur when unstained slides are stored for extended periods.

During the Procedure

The laboratory phase of Her 2-Neu / Ki67 staining at Chughtai Lab involves a series of highly technical, automated steps designed to preserve tissue morphology while maximizing antigen detection:

• Microtomy: A skilled histotechnologist cuts ultra-thin sections, measuring approximately 3 to 4 micrometers, from the patient’s paraffin block using a high-precision microtome. These sections are carefully transferred onto positively charged glass slides, which prevent the tissue from detaching during subsequent heating and washing steps.
• Deparaffinization and Rehydration: The slides are baked in an oven to melt the paraffin wax and then treated with a series of xylene baths to completely remove the wax. The tissue is then rehydrated by passing the slides through decreasing concentrations of ethanol and finally into distilled water.
• Antigen Retrieval: Formalin fixation causes protein cross-linking, which can mask the target epitopes of HER2 and Ki-67. To reverse this, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions (such as citrate or EDTA buffers) at controlled high temperatures, effectively unmasking the proteins.
• Blocking Endogenous Enzymes: The tissue is treated with hydrogen peroxide to block endogenous peroxidase activity, preventing non-specific background staining that could interfere with the final interpretation.
• Antibody Incubation: The slides are incubated with highly specific primary antibodies. One slide is treated with a monoclonal antibody targeting the extracellular domain of the HER2/neu receptor, while another slide is treated with a monoclonal antibody targeting the Ki-67 nuclear antigen.
• Signal Detection: A polymer-based secondary detection system is applied. This system contains secondary antibodies conjugated with horseradish peroxidase (HRP) enzymes that bind specifically to the primary antibodies, amplifying the signal.
• Chromogen Visualization: The slides are incubated with diaminobenzidine (DAB), a chromogenic substrate. The HRP enzyme catalyzes the oxidation of DAB, producing a highly visible, stable brown precipitate at the site of the target proteins. HER2/neu will show brown staining on the cell membrane, while Ki-67 will show brown staining within the cell nuclei.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin, which stains all cell nuclei blue, providing a clear contrast against the brown positive staining. The slides are then dehydrated, cleared, and sealed with a glass coverslip using a permanent mounting medium.
• Microscopic Analysis: A Consultant Pathologist evaluates the stained slides under a high-power light microscope to assess the staining patterns, intensity, and percentage of positive cells, translating these visual findings into a clinical report.

When is a Her 2-Neu / Ki67 (Staining) Performed?

Newly Diagnosed Invasive Breast Carcinoma

The primary and most common indication for performing Her 2-Neu / Ki67 staining is the initial diagnosis of invasive breast cancer. Every patient diagnosed with an invasive breast malignancy must have these biomarkers evaluated, alongside estrogen receptor (ER) and progesterone receptor (PR) status. This comprehensive biomarker panel is essential for molecular subtyping, which classifies breast cancers into distinct biological categories. This classification is the cornerstone of modern breast oncology, guiding the selection of systemic therapies and predicting overall survival and disease-free intervals.

Determining Eligibility for HER2-Targeted Therapies

Oncologists request HER2/neu staining specifically to determine if a patient is a candidate for HER2-targeted biological therapies. Drugs like trastuzumab (Herceptin), pertuzumab (Perjeta), and trastuzumab emtansine (T-DM1) have revolutionized the treatment of HER2-positive breast cancers, significantly improving survival rates. However, these therapies are only effective in tumors that overexpress the HER2 protein. The staining test acts as a critical gatekeeper, ensuring that only patients who will truly benefit from these targeted, high-cost, and potentially cardiotoxic medications receive them.

Assessing Tumor Proliferation and Aggressiveness

The Ki-67 staining is performed to measure the active growth fraction of the tumor. While histological grading provides a visual estimate of tumor differentiation, Ki-67 provides a quantitative measure of cell division. Physicians request this test to identify highly proliferative tumors that require aggressive systemic chemotherapy. A high Ki-67 index often tips the scale in favor of adding chemotherapy to the treatment regimen, especially in patients with hormone receptor-positive, HER2-negative breast cancers where the benefit of chemotherapy might otherwise be uncertain.

Evaluating Recurrent or Metastatic Disease

In cases where breast cancer recurs locally or metastasizes to distant sites such as the lungs, liver, bones, or brain, a biopsy of the metastatic lesion is highly recommended. Pathologists perform Her 2-Neu / Ki67 staining on the metastatic tissue because tumors can undergo biological changes over time—a phenomenon known as receptor discordance. A tumor that was originally HER2-negative may present as HER2-positive in its metastatic form, or vice versa. Re-evaluating these markers ensures that the treatment of metastatic disease is based on the current biological profile of the tumor.

Informing Neoadjuvant Chemotherapy Decisions

Neoadjuvant chemotherapy refers to systemic treatment administered before surgical resection of the tumor. It is commonly used to shrink large tumors, making them amenable to breast-conserving surgery rather than mastectomy, and to treat micrometastatic disease early. High Ki-67 levels and HER2-positive status are strong predictors of a pathological complete response (pCR)—meaning no active cancer cells are found in the breast tissue removed during surgery. Pathologists use these staining results to help oncologists identify patients who are ideal candidates for neoadjuvant therapy.

What Does a Her 2-Neu / Ki67 (Staining) Detect?

The Her 2-Neu / Ki67 staining panel detects specific cellular and molecular characteristics within the tumor tissue, providing a detailed biological profile. The key findings and parameters detected by this test include:

• HER2 Score 0 (Negative): No membrane staining is observed, or faint, incomplete membrane staining is present in less than 10% of the invasive tumor cells.
• HER2 Score 1+ (Negative): Faint, barely perceptible, incomplete membrane staining is observed in more than 10% of the invasive tumor cells.
• HER2 Score 2+ (Equivocal): Weak to moderate, complete circumferential membrane staining is observed in more than 10% of the invasive tumor cells. This result requires reflex testing via fluorescent in situ hybridization (FISH) to confirm gene amplification.
• HER2 Score 3+ (Positive): Strong, intense, and complete circumferential membrane staining is observed in more than 10% of the invasive tumor cells, confirming HER2 overexpression.
• Low Ki-67 Proliferation Index: Nuclear staining is present in less than 10% of the tumor cells, indicating a slow-growing, less aggressive tumor.
• Intermediate Ki-67 Proliferation Index: Nuclear staining is observed in 10% to 30% of the tumor cells, representing moderate proliferative activity.
• High Ki-67 Proliferation Index: Nuclear staining is present in more than 30% of the tumor cells, indicating a rapidly dividing, highly aggressive tumor.
• Luminal A Molecular Subtype: Identified by strong ER/PR positivity, HER2 negativity (Score 0 or 1+), and a low Ki-67 index (typically under 14%).
• Luminal B Molecular Subtype: Identified by ER/PR positivity and either HER2 positivity or HER2 negativity combined with a high Ki-67 index.
• HER2-Enriched Subtype: Identified by the absence of ER and PR expression, combined with strong HER2 positivity (Score 3+ or FISH amplified).
• Triple-Negative Breast Cancer (TNBC): Characterized by the complete absence of ER, PR, and HER2 expression, often showing a very high Ki-67 proliferation index.
• Intratumoral Heterogeneity: Detects variations in HER2 expression or Ki-67 proliferation rates across different regions of the same tumor specimen.
• Nuclear Staining Localization: Confirms that Ki-67 staining is localized strictly within the nuclei of the tumor cells, avoiding cytoplasmic artifacts.
• Membranous Staining Pattern: Evaluates the specific “chicken-wire” pattern of HER2 staining, which must be membranous and not cytoplasmic to be considered positive.
• Tissue Adequacy: Assesses whether the submitted biopsy sample contains a sufficient number of viable invasive tumor cells for reliable evaluation.
• Internal Control Validation: Verifies the staining quality by observing expected staining patterns in adjacent normal breast tissue or control tissues on the slide.
• Cold Ischemia Effects: Detects potential tissue degradation or weak staining resulting from delayed or inadequate formalin fixation.
• Mitotic Figures Correlation: Correlates high Ki-67 nuclear staining with the presence of active mitotic figures observed on standard H&E staining.
• Necrotic Areas: Identifies non-viable tumor regions where staining cannot be accurately interpreted, ensuring these areas are excluded from the final score.
• Invasive vs. In Situ Components: Distinguishes between invasive ductal carcinoma and ductal carcinoma in situ (DCIS), ensuring that HER2 and Ki-67 are scored only within the invasive component.
• Gastric Cancer Staining Patterns: Detects the unique basolateral or lateral membrane staining pattern characteristic of HER2-positive gastric and gastroesophageal junction adenocarcinomas.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we recognize that waiting for oncology test results can be a highly stressful experience for patients and their families. Because immunohistochemistry is a complex, multi-step process requiring precise laboratory preparation, automated staining, and meticulous microscopic evaluation, the turnaround time for the Her 2-Neu / Ki67 staining report is typically 3 to 5 working days. This timeframe ensures that every step of the pre-analytical and analytical phases is executed to the highest standards of quality and accuracy.

Once the Consultant Pathologist finalizes and signs off on the report, patients are immediately notified via an automated SMS alert. The complete, detailed diagnostic report can be accessed and downloaded online through the official Chughtai Lab web portal. Additionally, patients can use the My Chughtai mobile application to view, download, and share their results directly with their oncologist. For those who prefer physical copies, reports can be collected from any Chughtai Lab diagnostic center or collection point across Pakistan, or delivered directly to their home through our reliable home delivery service.

Her 2-Neu / Ki67 (Staining) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HER2/neu Expression (IHC Score)	Score 0 or 1+ (Negative; normal physiological levels of HER2 protein)	Score 2+ (Equivocal; requires FISH testing) or Score 3+ (Positive; HER2 protein overexpression)
Ki-67 Proliferation Index	Low index (typically <10% of tumor nuclei show staining; slow-growing tumor)	High index (typically >30%, indicating rapid cell division and aggressive tumor behavior)
Staining Localization Pattern	HER2: No membrane staining; Ki-67: Minimal nuclear staining in normal cells	HER2: Strong, continuous membranous staining; Ki-67: Dense, widespread nuclear staining
Molecular Subtype Classification	Luminal A-like profile (ER/PR positive, HER2 negative, low Ki-67)	Luminal B-like, HER2-enriched, or Triple-Negative breast cancer profiles
Internal Tissue Controls	Normal breast epithelium shows expected negative HER2 and low Ki-67 staining	Loss of staining in internal controls, indicating potential tissue degradation or fixation artifacts
Tumor Cell Viability	High percentage of viable, intact tumor cells suitable for staining evaluation	Extensive tumor necrosis, leading to uninterpretable staining patterns
Invasive Component Evaluation	Staining evaluated strictly within the invasive carcinoma component	Staining limited to ductal carcinoma in situ (DCIS) without an invasive component

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Her 2-Neu / Ki67 (Staining)?

• Expert Pathologists: Our histopathology department is led by highly experienced Consultant Pathologists specializing in oncopathology, ensuring accurate and reliable interpretation.
• State-of-the-Art Automation: We utilize advanced, fully automated immunohistochemistry staining platforms to minimize human error and ensure exceptional staining quality.
• Strict Quality Assurance: Chughtai Lab participates in international external quality assessment programs, maintaining rigorous standards of diagnostic precision.
• Comprehensive Oncology Panels: We offer a complete suite of breast cancer biomarkers, including ER, PR, HER2, and Ki-67, allowing for comprehensive molecular profiling.
• Convenient Digital Access: Patients can access their reports instantly online or via the My Chughtai mobile app, facilitating rapid sharing with their healthcare team.
• Nationwide Network: With a vast network of diagnostic centers and collection points across Pakistan, submitting tissue samples is highly convenient.
• Timely Reporting: We prioritize oncology cases to ensure that critical diagnostic reports are delivered promptly, preventing delays in cancer treatment.
• Patient-Focused Care: Our professional and compassionate staff are dedicated to providing a supportive, comfortable, and seamless diagnostic experience.